Germfree’s Post

We believe standardization is the key to achieving better patient care and access. In our a recent episode of the BioProcess International podcast, Josh Ludwig explored how a standardized manufacturing model can help address industry challenges and improve patient outcomes. Listen to the full conversation to learn how ScaleReady is driving this change: https://lnkd.in/gnpNKDPa #biotech #sustainability #manufacturing #cellandgenetherapy #patientcare #scaleready

"I think not only my naivete, but my stated lack of experience and knowledge really drove me to ask a lot of questions and be even... proud about not knowing. So I think that when you have a team of experts and the new team member comes and his boss or her boss, they are experts, sometimes it develops a culture of like people being timid about asking the stupid question in the room. And I think when you see the CEO asking the stupid question in the room, you feel much better about it." In Part 3 of The Biotech Startups Podcast conversation with Immunai CEO, Noam Solomon, a big theme is the power of humility and curiosity in driving innovation. In this episode we touch on: – Emphasizing the importance of fostering a culture where asking questions, even the "stupid" ones, is encouraged and valued – The strategic decision to build a physical lab, which set Immunai apart from being just a computational company – The interdisciplinary approach of merging immunology with computer science to tackle complex problems in precision medicine – The challenges and strategies of working with big pharmaceutical companies, including the delicate balance of internal R&D and external collaborations It’s another fascinating journey into the world of biotech, filled with valuable insights on leadership, innovation, and resilience. Head over to Apple Podcasts or Spotify for this episode and more stories only a biotech exec can tell! #biotechnology #lifesciences #podcast

Excited to announce the release of Episode 23 of BioTalk Unzipped! 🎙️   In this second half of our fascinating conversation with Scott Ogle, CEO of TruLab, Real-Time Technology for Clinical Trial Oversight, Dr. Chad Briscoe and I dive into key trends shaping the biotech industry and beyond. 🌐💡   💼 We explore surprising parallels between the banking and pharma industries, the game-changing role of digital twinning in clinical trials, and the evolving landscape of biotech funding.   Scott also shares personal insights on leadership, mentorship, and the impact of the Inflation Reduction Act on pharma innovation.   This episode is packed with valuable takeaways for anyone navigating the world of biotech and drug development.   🔍 Topics include:   ✔️Biotech funding and macroeconomic factors ✔️How AI-powered digital twinning could revolutionize clinical trials ✔️The importance of maintaining data integrity in decentralized trials ✔️The influence of family and mentorship on leadership   Scott is a very engaging and genuine guy whom I think you'll enjoy.   Don't miss this episode filled with practical advice, bold insights, and a fresh perspective on innovation in pharma!   🎧 The Episode: https://lnkd.in/gUg3EZfV   #BioTalkUnzipped #Biotech #PharmaInnovation #ClinicalTrials #Leadership #Mentorship #BiotechFunding #Podcast

“Driving Efficiencies Across the Life Sciences Value Chain with AI in Drug Development - with Nishtha Jain of Takeda” https://lnkd.in/dWcvMCAs Bringing new drugs and treatments to market is historically a costly and arduous process, which up until recently, has always been considered a built-in cost of the life sciences industry. On a recent episode of the ‘#AIinBusiness’ podcast, Takeda Head of Innovation and Digital Technology Nishtha Jain recognizes the historical backdrop of go-to-market costs while noting the enormous potential AI capabilities have in driving down costs and timespend across the life sciences value chain:

How are cutting-edge innovations shaping patient care? How are medicine launches done in Pharma? In our latest episode of Podcast Cruzamento, we sat down with Hugo Barbosa, MSc, whose journey from a small town in post-revolution Portugal to a global healthcare leader offers a unique perspective on the industry. Here are some key highlights from our conversation: 🌍 Clinical Trials: We break down the phases of clinical trials and the journey of bringing a new treatment to market. 🌍 Personalised Medicine: Discover how advancements in genomics and cell therapy are leading to treatments tailored for individual patients. 🌍 Market Strategies: Learn about the complexities of drug pricing, market access, and global launch strategies. 🌍 Digital Transformation: Explore how technology is revolutionising patient engagement and streamlining the drug development process. 🌍 Global Access: Hugo discusses efforts to ensure that innovative treatments reach underserved populations worldwide. Feel free to reach out and connect on LinkedIn. Let’s continue the conversation. 👉 This episode is also available on all podcast platforms like YouTube, Apple Podcasts, and Google Podcast: https://lnkd.in/dhrx6jcE (Cc Daniel Guedelha, Beatriz Isabel Cruzeiro, Maria Loureiro, Hélder Romão, Daniel Lewi, Luis Miguel Oliveira, Miguel Oliveira, Ph.D., Luís Rocha, Nuno Silva, Cristina Vaz de Almeida, Nuno Guimaraes, Hugo Cláudio Marques) #cruzamentopodcast #digital #digitaltransformation #saude #portugal #estrategia #criatividade #liderança #inovacao #science #technology #ciencia #tecnologia #InovaçãoTecnológica #Podcast

Take a look at the great interview with Sahirzeeshan (Sahir) Ali of Modi Ventures with Marcus Vinicius Martinez and Raion. Sahir talks about the launch of the Modi Ventures fund, AI interpreting the "Google Map" of the human body, health tech as an enabler of high-touch healthcare, trends we're following and more. Thanks to Laurence Cohen and Marcus Vinicius Martinez. #techbio #vcfunding #healthtech

🎙️Exclusive podcast release! Our CEO recently joined Yin He on the latest episode of the AWS Health Innovation Podcast. In this insightful conversation, Andrei Georgescu, Ph.D. delves into how Vivodyne enables human testing before clinical trials. Our innovative platform has the capacity to cultivate tens of thousands of human tissue models at scale, setting a new standard in the field. Key Highlights: 🔬 How our microfluidic platform revolutionizes drug discovery by providing unprecedented insights into human biology ⚡ The key innovation behind our bottom-up self-assembly approach to grow complex human tissues 🌱 How our platform aligns with ethical principles by displacing animal testing 🧠 The immense challenge we are tackling by enabling AI modeling of integrated human physiology 💡 Advice from our CEO for biotech entrepreneurs on embracing transformative innovation ... and so much more. 🔉 Listen on the Health Podcast Network, or wherever you listen to your podcasts: https://lnkd.in/dJcyhSPA #AWSHealthPod #Biotech #DrugDiscovery #MicrofluidicTechnology #HumanBiology #EthicalInnovation #BiotechStartup #DrugDevelopment #OrganOnAChip

In the latest episode of the #ParexelBiotech podcast series, “De-Risking Drug Development,” our host, Paul Bridges, and colleagues focus on critical decision points in phases IIb & III that can ultimately determine the success of your product. Join Sangeeta Budhia, Sinan B. Sarac (MD, MSc, PhD), and Amy Pace as they discuss how to accelerate development and opportunities to differentiate your product through innovative and adaptive trial designs. Learn about the importance of integrated evidence planning and the critical role of early value story development alongside target product profile (TPP) planning. Mitigate development risks and stand out among competitors by planning ahead. Listen here: https://lnkd.in/g9Kt5hGA #Biotech #TrialDesign #ClinicalDevelopment

🎙️ SPECIAL BIOMED PODCAST EDITION: Why the Gold Coast is on track to become a global biomed powerhouse - New 10-year growth strategy In this special podcast episode, host Estella Rodighiero dives deep into the origins, drivers and incredible potential of our booming biomedical industry, interviewing Dr Chris Davis, General Manager of Griffith University's Institute for Glycomics, and Dan Barr, Director of the Better Cities Group. Both have played a key role in the development of our new Gold Coast Emerging Biomedical Industry Study, released this week, which lays out a ten-year growth strategy for the sector. Twenty years ago, the Gold Coast had exactly zero biomed companies or institutions. Now now it’s a thriving innovation ecosystem anchored by the Gold Coast Health and Knowledge Precinct and the world-leading Institute for Glycomics, with forward-thinking startups and a top-10 global pharmaceutical company. You'll hear how this growth has not just happened by accident - it has required vision, investment in infrastructure, the right government policy settings, and most importantly, the Gold Coast’s highly collaborative and entrepreneurial spirit. The challenge for the next decade, addressed by the study, is strategic: how to support and enable a sector that's expected to grow at twice the rate of any other local industry, and attract the right investment to position the Gold Coast as one of the world's pre-eminent biomed and medtech cities. 🎧 To listen on our website, click here: https://lnkd.in/gJtW6yuM Click below for a quick video preview of the podcast.

🚨 New podcast alert! 🚨 Listen to "Ep03 (August 2024): rEView Insights - Dimitri Aubert" by The #rEView Podcast. We talk #ExtracellularVesicles, #science, #career, and the creation of Vesiculab! Dimitri shares his unique and visionary perspective about the extracellular vesicle field, from his early days working for iZON science, to the current day as the head of his own company. His ability to identify the needs of researchers in the EV field and possibilities for the future is something you won't want to miss. https://lnkd.in/gidDsusn